Skip to main content
. Author manuscript; available in PMC: 2022 Jul 8.
Published in final edited form as: Toxicol Appl Pharmacol. 2021 Dec 18;438:115830. doi: 10.1016/j.taap.2021.115830

Figure 4:

Figure 4:

Measured vs. concentrations of dibenzo[def,p]chrysene (DBC) and DBC metabolites in plasma (A-B) and urine (C-D), averaged across six human volunteers orally administered with an oral dose of 29 ng of DBC. Lines are physiologically based pharmacokinetic (PBPK) model simulations of data (6).